Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Savara Inc (NQ: SVRA ) 3.760 +0.110 (+3.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,542,384 Open 3.650 Bid (Size) 3.760 (2) Ask (Size) 3.790 (13) Prev. Close 3.650 Today's Range 3.545 - 3.805 52wk Range 3.115 - 5.700 Shares Outstanding 114,066,080 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Savara Announces New Employment Inducement Grant October 18, 2024 From Savara Inc. Via Business Wire Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting October 01, 2024 From Savara Inc. Via Business Wire Performance YTD -13.96% -13.96% 1 Month -18.97% -18.97% 3 Month -18.61% -18.61% 6 Month -20.00% -20.00% 1 Year +16.05% +16.05% More News Read More Savara Announces New Employment Inducement Grant September 27, 2024 From Savara Inc. Via Business Wire SVRA Stock Earnings: Savara Misses EPS for Q2 2024 August 12, 2024 Via InvestorPlace SVRA Stock Earnings: Savara Misses EPS for Q1 2024 May 09, 2024 Via InvestorPlace Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) September 27, 2024 From Savara Inc. Via Business Wire Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately September 24, 2024 From Savara Inc. Via Business Wire Savara to Host Analyst and Investor Webinar on September 30, 2024 September 23, 2024 From Savara Inc. Via Business Wire Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket September 09, 2024 Via Benzinga Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 September 08, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant September 06, 2024 From Savara Inc. Via Business Wire Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant August 16, 2024 From Savara Inc. Via Business Wire Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 August 15, 2024 From Savara Inc. Via Business Wire Savara Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Savara Inc. Via Business Wire Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock June 28, 2024 From Savara Inc. Via Business Wire Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? June 26, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 26, 2024 Via InvestorPlace Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) June 26, 2024 From Savara Inc. Via Business Wire Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) June 25, 2024 From Savara Inc. Via Business Wire 3 Penny Stocks Poised for Major Upside Over the Next 5 Years June 19, 2024 Via InvestorPlace 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition June 11, 2024 Via InvestorPlace Savara to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Savara Inc. Via Business Wire Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 May 19, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant May 16, 2024 From Savara Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
